You are here:
Vanderbilt Biostatistics Wiki
>
Main Web
>
Seminars
>
WednesdaySeminarSeries
>
MashaKocherginsky5Sep2018
(29 Aug 2018,
TawannaPeters
)
(raw view)
E
dit
A
ttach
%HEAD{ NAME="Masha Kocherginsky, !PhD" AFFILIATION="Northwestern University Feinberg School of Medicine" TITLE="Continuous Safety Monitoring in Large Phase I Cancer Clinical Trials with Multiple Dose Expansion Cohorts" IMAGELINK="https://coa.norc.org/img/kocherginsky.jpg" }%Traditional phase I oncology clinical trial designs have morphed into multiple, parallel phase I trials that incorporate concurrent expansion cohorts across multiple diseases or disease subtypes. These cohorts are used to provide additional safety data, as well as preliminary efficacy data. As a result, some of these Phase I trials have become quite large. For example, a recent study [Cancer Letter, 2016] examined PD-1 drug development, and identified 35 phase I trials with ≥200 patients. In such trials, dose escalation is typically done using a standard phase I design, e.g. “3+3”, to determine the maximum tolerated dose (MTD), which is followed by enrollment of multiple expansion cohorts in different disease types or biomarker-defined subgroups. Safety is typically monitored only within each expansion cohort, and the results are not jointly evaluated in real time across the multiple expansion cohorts. Here we propose to use a continuous safety monitoring approach based on the sequential probability ratio test (SPRT) and discuss its application to adverse event (AE) monitoring for large Phase I trials with multiple concurrent expansion cohorts. Trial designs based on this approach consist of a continuous safety monitoring boundary with a rejection number for each additional AE, and the rejection boundaries can be calculated using existing software. Based on our simulation studies and evaluation of the operating characteristics, we found that this is a practical approach which maintains Type I error rate and results in smaller average sample size than the current approach. %TAIL{DATE="5 September 2018"}% <!-- * Set HEAD = <div class="w3-card-2" id="task" style="max-width:750px; margin-left: 0px;"> <header class="w3-container w3-blue" style="padding:40px"><h1>Biostatistics Weekly Seminar</h1><br><h2 style="color:white;">%TITLE%<br><br>%NAME%<br>%AFFILIATION%</h2></header><div class="w3-container" style="padding:40px"><IMG SRC=%IMAGELINK% align="left" id="mug"/> * Set TAIL = <br><br><h3>MRBIII, Room 1220<br>%DATE%<br>1:30pm</h3></div></div><br>[[%TOPIC%Itinerary][Speaker Itinerary]] --> <style> .w3-card-2,.w3-example{box-shadow:0 2px 4px 0 rgba(0,0,0,0.16),0 2px 10px 0 rgba(0,0,0,0.12)!important} .w3-blue,.w3-hover-blue:hover{color:#fff!important;background-color:#2196F3!important} .w3-container{padding:0.01em 16px} .foswikiTopic {font-family: 'Open Sans', sans-serif;} /* Removes location hierarchy (usually written in grey text) */ .patternHomePath {display:none;} /* Removes bar with edit and attach buttons and location hierarchy */ .patternTop{display:none;} h1, h2, h3, h4, h5, h6{font-family: 'Montserrat','Open Sans', sans-serif;font-weight:700;} h1, h2, h3, h4, h5, h6{color:#bf1735;} h1:first-of-type{color:#2a3e6e;margin-bottom:25px;margin-top:5px;} .foswikiImage{margin-left:-9px;} img#mug{padding-right: 40px; padding-bottom:25px; height:250px;} </style>
E
dit
|
A
ttach
|
P
rint version
|
H
istory
: r4
<
r3
<
r2
<
r1
|
B
acklinks
|
V
iew topic
|
Edit
w
iki text
|
M
ore topic actions
Topic revision: r4 - 29 Aug 2018,
TawannaPeters
Main
Department Home Page
Biostatistics Graduate Program
Vanderbilt University Medical Center
Main Web
Main Web Home
Search
Recent Changes
Changes
Topic list
Biostatistics Webs
Archive
Main
Sandbox
System
Register
|
Log In
Copyright © 2013-2022 by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding Vanderbilt Biostatistics Wiki?
Send feedback